Search company, investor...
Search

Founded Year

2013

Stage

Series D | Alive

Total Raised

$24.24M

Last Raised

$9.22M | 7 mos ago

About Ybrain

Ybrain is a brain science healthcare company that commercializes home-based neuropsychiatry diagnosis, treatment, and management solutions for people with mental illnesses. The company's products include MINDD STIM, a medical-grade, noninvasive brain stimulation system that uses weak currents to stimulate the human brain and help patients suffering from mental health conditions such as depression; and MINDD SCAN, a wireless EEG system that allows operators to quickly complete preparation and collection of EEG signals.

Ybrain Headquarters Location

#228, 54, Changeop-ro Sujeong-gu, Seongnam-si, Gyeonggi-do

Republic of Korea, 13449,

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ybrain's Products & Differentiation

See Ybrain's products and how their products differentiate from alternatives and competitors

  • MINDD STIM+

    Electroceutical platform

    Differentiation

    Approved at home use transcranial direct current stimulation(tDCS) for depression through confirmatory clinical study under physician's prescription. 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Ybrain

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ybrain in 2 CB Insights research briefs, most recently on May 24, 2021.

Expert Collections containing Ybrain

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ybrain is included in 9 Expert Collections, including Digital Health.

D

Digital Health

13,541 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health Tech

1,246 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

W

Wearable Computing

411 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.

C

Conference Exhibitors

6,062 items

Companies that will be exhibiting at CES 2018

M

Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,876 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Ybrain Patents

Ybrain has filed 30 patents.

The 3 most popular patent topics include:

  • Neurophysiology
  • Electrotherapy
  • Neurotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/8/2019

7/19/2022

Neurophysiology, Neurotechnology, Electrophysiology, Neuroimaging, Neuroscience

Grant

Application Date

2/8/2019

Grant Date

7/19/2022

Title

Related Topics

Neurophysiology, Neurotechnology, Electrophysiology, Neuroimaging, Neuroscience

Status

Grant

Latest Ybrain News

08:00 EDT Ybrain Receives Translational Research Award 2022 Neuroergonomics Conference & NYC Neuromodulation Conference

Aug 18, 2022

News provided by Share this article Share this article NEW YORK, Aug. 18, 2022 /PRNewswire/ -- Ybrain recently received the Translational Research Award at this year's Neuroergonomics Conference and NYC Neuromodulation Conference held from July 28 to August 1 for its neuromodulation technology in transcranial direct current stimulation (tDCS). The highly sought-after recognition was conferred to researchers who made a significant contribution to the neuromodulation field with only two out of dozens of renowned scholars of neuromodulation being awarded. Kiwon Lee, CEO of Ybrain gives speech about 'at-home' electroceutical for the treatment of major depressive disorder. The conferences were joined together to address the state-of-the-art neurotechnology for brain-body performance and health. It focused on the latest approaches for both brain function and dysfunction including brain/body performance, depression, skill acquisition, stress and fatigue, pain, addiction and binge eating, cognition and physical recovery, eye-tracking, neuromarketing, and remote/mobile sensing. These themes were intended to encourage discussion that crossed traditional sub-domains of neurotechnology. Ybrain's award-winning neuromodulation technology, tDCS, is designed for the treatment of major depressive disorder and tDCS caters to patients that wish to manage use of antidepressants as a form of treatment. tDCS is used in the company's MINDD-STIM+ treatment. This is especially relevant in today's post-pandemic world as COVID-19 resulted in a surge of new cases. For some individuals, major depressive disorder can give rise to severe impairments that disrupt or limit an individual's ability to perform major life activities. It is estimated that in 2020, 21 million adults in the US had at least one depressive episode, with a higher incidence amongst females rather than males and individuals aged between 18 and 25 years. With the COVID-19 pandemic, 32.8%  of American adults experienced elevated depressive symptoms in 2021 as compared to 8.5% before the pandemic. "We hope that our 'at-home electroceutical treatment' will be used as the new neuromodulation technology to solve the mental health problems exacerbated by the COVID-19 pandemic," says Kiwon Lee, CEO of Ybrain. "With the alleged increase in the patient population with depression in the US, Ybrain's new MINDD-STIM+ hopes to bring an electroceutical alternative to patients who are averse to using antidepressants, right from the comfort of their own home." People suffering from depression may choose to control antidepressants for one of many reasons. Serotonin reuptake inhibitors, a type of drug commonly used to treat depression that increases serotonin levels at nerve junctions, do not work for approximately 30% of the population with major depressive disorder. Furthermore, the prolonged use of antidepressants has made it difficult for some to call quits, experiencing dizziness, confusion, fatigue, and other common symptoms of drug withdrawal. The 2022 Neuroergonomics Conference & NYC Neuromodulation Conference brought together visitors from academia and companies alike, paving the way for future collaborations and partnerships for Ybrain. According to Ybrain officials, treating major depressive disorder is the first step, with clinical trials for schizophrenia, dementia, stroke, and Parkinson's disease well underway. Aiming to penetrate the American market, Ybrain has submitted and expected the clearance of MINDD-STIM+ as De Novo from FDA early next year. About Ybrain Established in 2013 in South Korea, Ybrain develops medical devices that measure, and cure neuropsychiatric diseases based on neuroscience. The company provides wearable devices(electroceutical) based on tDCS that cure Major Depressive Disorder (MDD) and other psychiatric illnesses with its digital platform. Led by a diverse group of experts in neuroscience, software, and electronic engineering, Ybrain aims to offer accessible mental health treatment to everyone through electroceuticals. For more information, visit https://www.ybrain.com/en/ . SOURCE Ybrain

Ybrain Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ybrain Rank

  • When was Ybrain founded?

    Ybrain was founded in 2013.

  • Where is Ybrain's headquarters?

    Ybrain's headquarters is located at #228, 54, Changeop-ro, Republic of Korea.

  • What is Ybrain's latest funding round?

    Ybrain's latest funding round is Series D.

  • How much did Ybrain raise?

    Ybrain raised a total of $24.24M.

  • Who are the investors of Ybrain?

    Investors of Ybrain include Ceragem, KT&G, InterVest, NEOFECT, G.N. Tech Venture Capital and 12 more.

  • Who are Ybrain's competitors?

    Competitors of Ybrain include Calm and 5 more.

  • What products does Ybrain offer?

    Ybrain's products include MINDD STIM+ and 4 more.

You May Also Like

W
Wisear

Wisear develops a patented technology enabling any earphones to record & analyze the user's the brain & facial activity.

Headspace Logo
Headspace

Headspace develops an online membership platform offering free guided meditation and mindfulness to feel happier, sleep better and beat stress.

N
Norstella

Norstella is a group of pharmaceutical solutions providers offering clients tools and expertise to navigate complexities for each step of the drug development life cycle, from pipeline to patient. The company is based in Morrisville, Pennsylvania.

T
TBT Pharma

TBT is a dermatology start up with novel mechanisms of action by re-purposing generic and off patent compounds approved for oral and IV use for topical use.

Ditch Labs Logo
Ditch Labs

Ditch Labs is a smoking cessation platform that develops devices, digital therapeutics, and AI-driven solutions to solve health problems. It is based in Montreal, Quebec.

G
GrayMatters Health

GrayMatters Health (GMH) develops digital, self-neuromodulation therapeutics for mental disorders to help patients regain agency over their emotion regulation. GMH offers Prism, a non-invasive adjunct therapeutic that utilizes neuroscience-based and brain-mechanism-specific biomarkers. The company's first product candidate, Prism for PTSD, is undergoing clinical investigation in five sites across the United States and Israel to demonstrate its efficacy and safety as an adjunct to standard PTSD treatments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.